NCI metastatic HER2 trial
this trial info was sent to MBCN... maybe someone is interested???
CALL FOR PATIENTS
The Surgery Branch of the National Cancer Institute has just opened an exciting new protocol for the treatment of patients with Her2 positive metastatic breast cancer using a new approach to immunotherapy that uses a patient's own cells that have been genetically modified to recognize and attack the cancer.
Only patients with breast cancers that express Her2 and who have progressed through standard treatment are eligible for this experimental therapy. There is no charge for patients treated at the National Cancer Institute.
The appropriate contacts for referral of patients are:
Linda Williams, RN
June Kryk, RN
Surgery Branch Referral Office
301-451-1929
|